跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05510999
NCT05510999已完成2 期

A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Efficacy of Graminex® Flower Pollen Extracts in Healthy Women With Urinary Incontinence.

Graminex LLC2 个研究点 分布在 1 个国家目标入组 190 人开始时间: 2019年6月17日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
190
试验地点
2
主要终点
The change in severity of urinary incontinence between baseline and 24 weeks.
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The primary objective of this study is to investigate the effect of Graminex® Flower Pollen Extracts in healthy women with urinary incontinence. The change in severity of urinary incontinence between baseline and 24 weeks will be assessed by an International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF), and compared between the investigational product and placebo groups. Additionally, the safety and tolerability of Graminex® Flower Pollen Extracts, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
40 Years 至 75 Years（Adult, Older Adult）
性别
Female
接受健康志愿者
是

入选标准

  • •Females between the ages of 40-75 inclusive.
  • •BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive.
  • •Involuntary loss of urine (incontinence) persisting for at least 1 month as determined by a score ≥ 5 on the ICIQ-SF questionnaire at the screening visit.
  • •Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening.
  • •Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
  • •Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
  • •Double-barrier method
  • •Intrauterine devices
  • •Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
  • •Vasectomy of partner at least 6 months prior to screening
  • •Agree to keep lifestyle habits consistent (dietary habits and physical activity patterns) for the duration of the trial.
  • •Willing to maintain current caffeine intake. Individuals with excessive habitual caffeine intake (>3 cups coffee or >4 cups caffeinated tea per day or >2 energy drinks) will be required to reduce consumption for 2 weeks prior to baseline.
  • •Healthy as determined by laboratory results, medical history, and physical exam.
  • •Has given voluntary, written, informed consent to participate in the study.

排除标准

  • •Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.
  • •Allergy or sensitivity to test product ingredients.
  • •Treatment (ie. pessary) or surgery (ie. sling, mesh) for urinary incontinence from a continence specialist (ie. urologist, urogynecologist, gynecologist) within the past 5 years.
  • •Treatment for overactive or neurogenic bladder in previous 3 months (ie. neuromodulation, botox).
  • •Initiation of pelvic floor therapy in the previous 3 months.
  • •Current utilization of a catheter for urination.
  • •Current urinary tract infection (UTI, confirmed by laboratory analysis), verbal confirmation of infection in previous 3 months or history of recurrent UTIs.
  • •Women who are currently taking medications for urinary incontinence/overactive bladder (see Section 6.3.1).
  • •Irregular menstrual periods within the previous 6 months (less than 21 or greater than 33 days between cycles).
  • •Women who are within 1-year postpartum.
  • •Genital malformation (i.e. Vaginal fistula) or vaginal and/or vulvar disorder (i.e. vulvovaginal atrophy).
  • •Women on hormone replacement therapy (oral or topical), unless on a stable dose for ≥6 months.
  • •Metal implants that may affect the DXA scan results will be assessed on case-by-case basis by the QI.
  • •Current, chronic constipation reviewed on a case-by-case basis by the QI.
  • •Current or history of diabetes.
  • •Current or history of bladder tumour.
  • •Current sexually transmitted infection (confirmed by laboratory analysis), or verbal confirmation of infection in previous 3 months.
  • •Current or history of liver, kidney or heart disease.
  • •Current or pre-existing unstable thyroid condition. Treatment on a stable dose of medication for over one year will be reviewed on a case-by-case basis by the QI .
  • •Current or history of bleeding disorders.
  • •Clinically significant abnormal laboratory results at screening.
  • •Excessive consumption of alcohol equivalent to >2 alcoholic drinks/day (average).
  • •Alcohol or drug abuse within the last 6 months.
  • •Individuals who are cognitively impaired and/or who are unable to give informed consent.
  • •Any autoimmune disease or immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive).
  • •Participation in other clinical research trials one month prior to or during enrollment will be assessed case-by-case by the QI.
  • •Any other condition, that, in the opinion of the QI, may adversely affect the participant's ability to provide written informed consent and complete the study or its measures, or pose significant risk to the participant.

结局指标

主要结局

The change in severity of urinary incontinence between baseline and 24 weeks.

时间窗: baseline and 24 weeks

The change in severity of urinary incontinence between baseline and 24 weeks as assessed by the ICIQ-SF will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.

次要结局

  • The change in severity of urinary incontinence between baseline and week 6, 12, and 18.(baseline, week 6, week 12, week 18)
  • The change in degree of bother between baseline and weeks 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in frequency of urinary incontinence between baseline and week 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in frequency of nocturia between baseline and week 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in frequency of daytime urination between baseline and week 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in bone density between baseline and week 24.(baseline, week 24)
  • The change in incontinence-related quality of life between baseline and weeks 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • Aspartate aminotransferase (AST) measurement following a 24-week supplementation.(24 weeks)
  • Estimated glomerular filtration rate (eGFR) measurements following a 24-week supplementation.(24 weeks)
  • The change in stress-induced urinary leakage volume between baseline and week 24.(baseline, week 24)
  • Creatinine measurement following a 24-week supplementation.(24 weeks)
  • Hematocrit measurements following a 24-week supplementation.(24 weeks)
  • Bilirubin measurement following a 24-week supplementation.(24 weeks)
  • Platelet count measurements following a 24-week supplementation.(24 weeks)
  • The change in daily urinary leakage volume between baseline and week 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in sleep quality between baseline and weeks 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The change in Lower Urinary Tract Symptom Score (LUTSS) between baseline and weeks 6, 12, 18, and 24.(baseline, week 6, week 12, week 18, week 24)
  • The incidence of pre-emergent and post-emergent adverse events during a 24-week supplementation period.(24 weeks)
  • Vital sign measurements (heart rate; HR) during a 24-week supplementation period.(baseline, week 6, week 12, week 18, week 24)
  • Measurement of electrolytes following a 24-week supplementation.(24 weeks)
  • White blood cell measurements following a 24-week supplementation.(24 weeks)
  • Red blood cell measurements following a 24-week supplementation.(24 weeks)
  • Hemoglobin measurements following a 24-week supplementation.(24 weeks)
  • Mean corpuscular hemoglobin following a 24-week supplementation.(24 weeks)
  • Vital sign measurements (blood pressure; BP) during a 24-week supplementation period.(baseline, week 6, week 12, week 18, week 24)
  • Alanine aminotransferase (ALT) measurement following a 24-week supplementation.(24 weeks)
  • Mean corpuscular volume following a 24-week supplementation.(24 weeks)
  • Red cell distribution width following a 24-week supplementation.(24 weeks)
  • Mean corpuscular hemoglobin concentration following a 24-week supplementation.(24 weeks)

研究者

发起方
Graminex LLC
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

已完成
3 期
Grass Pollen Immunotherapy Using a Cluster Regime for Seasonal Rhinitis and AsthmaRhinitis, Allergic, Seasonal
NCT00135642Imperial College London44
已完成
3 期
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen MixtureGrass Pollen Allergy
NCT00264459Allergopharma GmbH & Co. KG160
已完成
不适用
Effect of Pollen Challenges on Dermal Symptoms in Patients With Atopic DermatitisAtopic Dermatitis
NCT01475994Fraunhofer-Institute of Toxicology and Experimental Medicine18
Unknown
不适用
Dietary Supplementation on Gastrointestinal Barrier FunctionIntestinal Permeability
NCT06262880Brightseed126
招募中
不适用
Dietary Supplementation on Body Fat CompositionDyslipidemiasPre-diabetes
NCT06296251Brightseed150